A Randomized, Double Blind, Controlled, Phase 3 Clinical Trial of Standard of Care with or without Siltuximab in Selected Hospitalized Patients with COVID-19 Previously Treated with Corticosteroids or Another Respiratory Virus Infection Associated with Acute Respiratory Distress Syndrome and Elevated C-Reactive Protein Levels.
Contact phone
Sparrow Clinical Research Institute 517.364.5760
Principal investigator
Rajit Pahwa, M.D.
Trial Category
Internal Medicine
Trial SubCategory